Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 17 December 2025 - 21 December 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. (NYSE: PFE) is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing. As of the most recent close (Friday, Dec. 19), Pfizer stock finished around $25.19, leaving shares squarely in the “mid‑$20s” range where they’ve been pinned for much of the post-pandemic reset. MarketBeat+1 What changed in December—and why investors are still arguing about Pfizer stock—comes down to three big storylines: Below is a comprehensive, up-to-date roundup of
21 December 2025
·····
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters+1 Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing whether the company’s cost-cutting and deal-making can offset the twin headwinds of fading COVID-era revenue and a looming patent cliff. Yahoo Finance+1 Why Pfizer stock is moving: the 2026 forecast reset The biggest driver of this week’s debate is Pfizer’s
21 December 2025
·····
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds (shrinking COVID-era revenue, a growing patent cliff, and U.S. drug-pricing pressure) and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing.com That price level matters because it frames the debate investors are having right now: Is PFE a high-yield “wait-it-out” turnaround, or a value trap until new launches and major clinical wins begin to offset upcoming losses of exclusivity? Below is a
21 December 2025
·····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock (NYSE: PFE) is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation (MFN) framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent cliff and the long fade of COVID-era revenue. Reuters+1 Pfizer stock price snapshot: where PFE stands on Dec. 20, 2025 With U.S. markets closed for the weekend, the latest available quote has Pfizer shares around $25.19, after a volatile stretch
20 December 2025
·····
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) is ending the week with investors weighing a cautious 2026 outlook against fresh pipeline momentum and a fast-moving U.S. drug-pricing policy backdrop. As of the latest available quote on Friday, Dec. 19, 2025, Pfizer shares traded around $25.37, up about 1.3% on the day, with an intraday range of roughly $24.99 to $25.52 and volume near 43.5 million shares. Below is what’s driving Pfizer stock right now, what management and analysts are forecasting, and what catalysts investors are watching into 2026. Pfizer stock price action on Dec. 19, 2025: why PFE is in focus Pfizer’s share
19 December 2025
····
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) stock was essentially flat on Friday, Dec. 19, 2025, trading around $25.04 in midday trading, after a volatile week that blended policy headlines, a reset of near-term financial expectations, and fresh pipeline updates. For investors, the story around Pfizer stock right now is less about a single headline and more about a three-way tug-of-war: Below is a roundup of the most consequential Pfizer stock news, forecasts, and analysis points investors are digesting as of 19.12.2025. Pfizer stock price today: PFE steadies near $25 as investors weigh policy and guidance As of 14:16 UTC on Dec. 19,
19 December 2025
·····
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. (NYSE: PFE) ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at $25.04. Google Below is what moved the conversation around Pfizer today, what the latest forecasts imply, and the key items to monitor before the stock market opens Friday (Dec. 19, 2025). Pfizer stock after the bell: where PFE stands heading
19 December 2025
·····
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer (NYSE: PFE) stock is trying to regain its footing on Thursday, December 18, 2025, after a volatile mid-December stretch that put the spotlight back on three recurring themes for shareholders: the post-COVID revenue reset, looming loss-of-exclusivity (LOE) headwinds, and whether Pfizer’s rebuilt pipeline can drive durable growth later this decade. As of 18:26 UTC (1:26 p.m. ET) on Dec. 18, Pfizer shares traded around $25.04, essentially flat on the day. What’s driving Pfizer stock on Dec. 18, 2025 Here are the major, market-moving Pfizer headlines and developments investors are digesting today: Pfizer stock price check: stability after a sharp
18 December 2025
··
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Inc. (NYSE: PFE) stock is trying to steady itself in late December after a volatile stretch driven by one big theme: the post-COVID hangover is still real, and 2026 is shaping up as another “rebuild” year—even as Pfizer spends aggressively to reload its pipeline. As of Thursday, Dec. 18, 2025, Pfizer shares traded around $25.04, down about 1.8% from the prior close, according to the latest available trade time in the market feed. What’s making Pfizer stock interesting right now isn’t a single headline—it’s the collision of several: Below is a detailed, publication-ready roundup of the most current news,
18 December 2025
·····
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer (NYSE: PFE) finished Wednesday’s session lower and traded only modestly in the after-hours market—an indication that investors are still digesting the company’s newly issued 2026 outlook while weighing fresh pipeline headlines and looming U.S. policy risk around drug pricing. Below is a detailed look at where Pfizer stock stands after the bell on Dec. 17, 2025, what news moved the narrative today, where Wall Street’s forecasts are landing, and what to watch before the opening bell Thursday, Dec. 18, 2025. Pfizer stock after the bell: the numbers investors are watching Pfizer shares closed at $25.04 on Wednesday, down about
18 December 2025
·····
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Inc. stock (NYSE: PFE) is back in the spotlight on Wednesday, December 17, 2025, as investors digest the drugmaker’s newly issued 2026 outlook, a revised 2025 revenue view, and a longer runway to sustained growth than some shareholders had hoped for. Shares were trading around the mid-$25 range today, following a sharp reaction to the guidance update earlier this week. The big question now: is Pfizer stock a high-yield value play that’s building a post-COVID, post-patent-cliff pipeline—or a “show me” story that will remain range-bound until revenue growth becomes visible? Below is a full roundup of the most important
17 December 2025
····
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Inc. (NYSE: PFE) is back in the spotlight on Wednesday, Dec. 17, 2025, as investors digest a fresh set of financial targets for 2026, updated 2025 revenue expectations, and a growing pile of “what matters next” questions about the company’s post-COVID trajectory. In late-morning trading, Pfizer stock hovered around $25.53, down about 3.4% on the day, reflecting a cautious market reaction to management’s outlook and the company’s longer roadmap through a multi-year patent-expiration cycle. Below is what’s moving Pfizer stock today, what the company just guided for 2026, how analysts are framing the setup, and the pipeline and policy
17 December 2025
·····
1 … 5 6 7 8 9 10

Stock Market Today

REA share price tumbles after results as listings outlook bites; buyback and dividend dates loom

REA share price tumbles after results as listings outlook bites; buyback and dividend dates loom

7 February 2026
Sydney, Feb 7, 2026, 16:49 AEDT — Market closed REA Group shares closed down 7.8% on Friday at A$168.10 after the online property advertising group laid out a softer listings outlook. The stock opened sharply lower at A$150.01 and traded in a A$150.01–A$172.80 range. (Investing.com Australia) The drop landed in a broad risk-off session, with the ASX 200 ending about 2% lower. “Panic is spreading,” said Michael McCarthy at MooMoo Australia, as investors headed for the exits across markets. (ABC News) REA said revenue from core operations — which strips out one-off items — rose 5% to A$916 million in
CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

7 February 2026
CSL Limited shares closed down 0.4% at A$180.50 Friday as the S&P/ASX 200 dropped 2.03% to 8,708.80. CSL will report half-year results and announce its interim dividend on Feb. 11, with the stock set to trade ex-dividend March 10. A filing showed 59,992 CSL conditional rights lapsed this week. The company’s market value stands near A$87 billion, down about a third in the past year.
Go toTop